The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, of Novartis Pharmaceuticals Corporation. Pazopanib Tablets, is indicated for the treatment of adults with advanced renal cell carcinoma (RCC), and advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The product is expected to be launched in Q4 FY25. The approved product has an estimated market size of $106 million for the twelve months ending October 2024, according to IQVIA. This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Shares of Aurobindo Pharma declined 0.98% to Rs 1,245.70 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. The product is expected to be launched in Q4FY25. The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA. This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Pazopanib Tablets, 200 mg is indicated for the treatment of adults with Advanced Renal Cell Carcinoma (RCC), and Advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.Powered by Capital Market - Live

The headline equity benchmarks continued to trade with major gains in morning trade after the outcomes of the Maharashtra and Jharkhand elections. Additionally, macroeconomic indicators, including GDP and infrastructure output, will garner significant attention. The Nifty hovered above the 24,300 level. PSU bank shares extended gains for the second consecutive trading session. At 10:30 ST, the barometer index, the S&P BSE Sensex, soared 1,256.78 points or 1.59% to 80,394.32. The Nifty 50 index surged 408.10 points or 1.71% to 24,315.35. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index added 1.89% and the S&P BSE Small-Cap index gained 1.88%. The market breadth was strong. On the BSE, 2,888 shares rose and 805 shares fell. A total of 200 shares were unchanged. Economy: India's foreign exchange reserves declined $17.761 billion, reaching $657.892 billion for the week ended November 15, as reported by the RBI on Friday. In the prior week ending November 8, the forex declined $6.477 billion to $675.653 billion. The central bank also reported that gold reserves reduced by $2.068 billion to $65.746 billion during this period. It also indicated that Special Drawing Rights (SDRs) decreased by $94 million to $18.064 billion. Additionally, India's reserve position with the IMF also declined by $51 million, reaching $4.247 billion in the reporting week. Buzzing Index: The Nifty PSU Bank index gained 4.62% to 6,808.75. The index advanced 7.75% in two consecutive trading sessions. Indian Bank (up 8.82%), UCO Bank (up 7.67%), Central Bank of India (up 5.33%), Punjab & Sind Bank (up 5.24%) and Punjab National Bank (up 4.91%), Indian Overseas Bank (up 4.81%), Bank of Baroda (up 4.43%), Union Bank of India (up 4.26%), Canara Bank (up 3.79%) and Bank of Maharashtra (up 3.76%). edged higher. Stocks in Spotlight: Aurobindo Pharma added 1.41% after the company's wholly owned subsidiary, Aurobindo Pharma USA Inc entered into a collaboration and license agreement with a global pharma major. Bliss GVS Pharma gained 2.24% after the company's Maharashtra-based facilities received a GMP compliance certificate from the National Agency for Medicines and Medical Devices of Romania post an EU GMP inspection. Powered by Capital Market - Live

The agreement is for development of specific products across respiratory therapeutic area and their commercialisation. The agreement is for an initial estimated development duration of three- five years. Both the parties will collaborate with respect to the development of specific products across respiratory therapeutic area. Both the parties will co-exclusively commercialize the product. The products, once commercialized, will be manufactured at partner's facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date. A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of $90 million for Aurobindo over the development period. Aurobindo would make an upfront payment of $25 million, on the effective date of the agreement. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

Aurobindo Pharma USA Inc., a wholly owned subsidiary of Aurobindo Pharma, has entered into a collaboration and license agreement on 22 November 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.Powered by Capital Market - Live

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1265.85, down 4.65% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24233.2. The Sensex is at 79752.86, up 0.34%.Aurobindo Pharma Ltd has eased around 15% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 5.71% in last one month and is currently quoting at 22542.25, down 0.95% on the day. The volume in the stock stood at 23.08 lakh shares today, compared to the daily average of 8.02 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1269.35, down 4.92% on the day. Aurobindo Pharma Ltd jumped 29.25% in last one year as compared to a 24.11% rally in NIFTY and a 43.47% spurt in the Nifty Pharma index.The PE of the stock is 40.7 based on TTM earnings ending June 24.Powered by Capital Market - Live

Net profit of Aurobindo Pharma rose 7.95% to Rs 817.38 crore in the quarter ended September 2024 as against Rs 757.18 crore during the previous quarter ended September 2023. Sales rose 6.93% to Rs 7646.21 crore in the quarter ended September 2024 as against Rs 7150.71 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales7646.217150.71 7 OPM %20.4819.21 - PBDT1589.741493.14 6 PBT1207.461075.64 12 NP817.38757.18 8 Powered by Capital Market - Live

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS Pharma on 25 October 2024. With this transaction, GLS Pharma has become a wholly owned subsidiary of the Company.Powered by Capital Market - Live

Aurobindo Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1509.05, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 25134.8. The Sensex is at 82005.72, up 0.45%. Aurobindo Pharma Ltd has slipped around 0.62% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 2.13% in last one month and is currently quoting at 23307.95, up 1.91% on the day. The volume in the stock stood at 3.63 lakh shares today, compared to the daily average of 13.57 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1519, up 1.41% on the day. Aurobindo Pharma Ltd is up 67.5% in last one year as compared to a 27.65% spurt in NIFTY and a 57.23% spurt in the Nifty Pharma index.The PE of the stock is 45.69 based on TTM earnings ending June 24.Powered by Capital Market - Live